Combined molnupiravir-nirmatrelvir treatment improves the inhibitory effect on SARS-CoV-2 in macaques

Combined molnupiravir-nirmatrelvir treatment improves the inhibitory effect on SARS-CoV-2 in macaques

The periodic emergence of SARS-CoV-2 variants of concern (VOCs) with unpredictable clinical severity and ability to escape preexisting immunity emphasizes the continued need for antiviral interventions. Two small molecule inhibitors, molnupiravir (MK-4482), a nucleoside analog, and nirmatrelvir (PF-...

Full description

Bibliographic Details
Main Authors:	Kyle Rosenke, Matt C. Lewis, Friederike Feldmann, Eric Bohrnsen, Benjamin Schwarz, Atsushi Okumura, W. Forrest Bohler, Julie Callison, Carl Shaia, Catharine M. Bosio, Jamie Lovaglio, Greg Saturday, Michael A. Jarvis, Heinz Feldmann
Format:	Article
Language:	English
Published:	American Society for Clinical investigation 2023-02-01
Series:	JCI Insight
Subjects:	COVID-19
Online Access:	https://doi.org/10.1172/jci.insight.166485

Similar Items

Molnupiravir inhibits SARS-CoV-2 variants including Omicron in the hamster model
by: Kyle Rosenke, et al.
Published: (2022-07-01)

Histopathologic Characterization of Experimental Peracute SARS-CoV-2 Infection in the Syrian Hamster
by: Chad S. Clancy, et al.
Published: (2023-08-01)

Molnupiravir and Nirmatrelvir/Ritonavir: The New Available Antiviral Options for COVID-19
by: Samuel Theodorus Sutanto, et al.
Published: (2022-12-01)

Molnupiravir and Nirmatrelvir/Ritonavir: Tolerability, Safety, and Adherence in a Retrospective Cohort Study
by: Maria Mazzitelli, et al.
Published: (2023-01-01)

Intradermal delivery of a synthetic DNA vaccine protects macaques from Middle East respiratory syndrome coronavirus
by: Ami Patel, et al.
Published: (2021-05-01)

Route of Francisella tularensis infection informs spatiotemporal metabolic reprogramming and inflammation in mice.
by: Forrest Jessop, et al.
Published: (2023-01-01)

Route of Francisella tularensis infection informs spatiotemporal metabolic reprogramming and inflammation in mice
by: Forrest Jessop, et al.
Published: (2023-01-01)

Efficacy of Sotrovimab (SOT), Molnupiravir (MOL), and Nirmatrelvir/Ritponavir (N/R) and Tolerability of Molnupiravir in Outpatients at High Risk for Severe COVID-19
by: Victoria Kauer, et al.
Published: (2023-05-01)

An atlas of gross and histologic lesions and immunohistochemical immunoreactivity during the temporal progression of aerosolized Lassa virus induced hemorrhagic fever in cynomolgus macaques
by: Forrest Bohler, et al.
Published: (2024-02-01)

Comparing Molnupiravir to Nirmatrelvir/Ritonavir (Paxlovid) in the Treatment of Mild-to-Moderate COVID-19 in Immunocompromised Cancer Patients
by: Andrea J. Haddad, et al.
Published: (2024-03-01)

Comparing molnupiravir and nirmatrelvir/ritonavir efficacy and the effects on SARS-CoV-2 transmission in animal models
by: Robert M. Cox, et al.
Published: (2023-08-01)

Interactions of the Anti-SARS-CoV-2 Agents Molnupiravir and Nirmatrelvir/Paxlovid with Human Drug Transporters
by: Éva Bakos, et al.
Published: (2023-07-01)

Nirmatrelvir/Ritonavir and Molnupiravir in the Treatment of Mild/Moderate COVID-19: Results of a Real-Life Study
by: Ivan Gentile, et al.
Published: (2022-10-01)

Association of Molnupiravir and Nirmatrelvir-Ritonavir with reduced mortality and sepsis in hospitalized omicron patients: a territory-wide study
by: Abraham Ka-chung Wai, et al.
Published: (2023-05-01)

Distinct VSV-based Nipah virus vaccines expressing either glycoprotein G or fusion protein F provide homologous and heterologous protection in a nonhuman primate modelResearch in context
by: Emmie de Wit, et al.
Published: (2023-01-01)

Lassa Virus Treatment Options
by: Frederick Hansen, et al.
Published: (2021-04-01)

Oral Molnupiravir and Nirmatrelvir/Ritonavir for the Treatment of COVID-19: A Literature Review with a Focus on Real-World Evidence
by: Ioannis Karniadakis, et al.
Published: (2023-10-01)

Comparison of azvudine, molnupiravir, and nirmatrelvir/ritonavir in adult patients with mild-to-moderate COVID-19: a retrospective cohort study
by: Mei-Ping Chen, et al.
Published: (2024-02-01)

Defining the Syrian hamster as a highly susceptible preclinical model for SARS-CoV-2 infection
by: Kyle Rosenke, et al.
Published: (2020-01-01)

The Combination of Molnupiravir with Nirmatrelvir or GC376 Has a Synergic Role in the Inhibition of SARS-CoV-2 Replication In Vitro
by: Anna Gidari, et al.
Published: (2022-07-01)

<i>Mastomys natalensis</i> Has a Cellular Immune Response Profile Distinct from Laboratory Mice
by: Tsing-Lee Tang-Huau, et al.
Published: (2021-04-01)

Real-World Effectiveness Study of Nirmatrelvir-Ritonavir or Molnupiravir in Hospitalized Unvaccinated Patients with Chronic Respiratory Diseases and Moderate COVID-19 at Presentation
by: Kwok WC, et al.
Published: (2024-01-01)

Comparative Evaluation of GS-441524, Teriflunomide, Ruxolitinib, Molnupiravir, Ritonavir, and Nirmatrelvir for In Vitro Antiviral Activity against Feline Infectious Peritonitis Virus
by: Subarna Barua, et al.
Published: (2023-08-01)

Real-World Experience of the Comparative Effectiveness and Safety of Molnupiravir and Nirmatrelvir/Ritonavir in High-Risk Patients with COVID-19 in a Community Setting
by: Yoshikazu Mutoh, et al.
Published: (2023-03-01)

Immunological correlates of protection afforded by PHV02 live, attenuated recombinant vesicular stomatitis virus vector vaccine against Nipah virus disease
by: Thomas P. Monath, et al.
Published: (2023-09-01)

Effectiveness, Tolerability and Prescribing Choice of Antiviral Molecules Molnupiravir, Remdesivir and Nirmatrelvir/r: A Real-World Comparison in the First Ten Months of Use
by: Cosmo Del Borgo, et al.
Published: (2023-04-01)

Effectiveness of molnupiravir vs nirmatrelvir-ritonavir in non-hospitalised and hospitalised patients with COVID-19: a target trial emulation studyResearch in context
by: Eric Yuk Fai Wan, et al.
Published: (2023-10-01)

Three-Week Old Pigs Are Not Susceptible to Productive Infection with SARS-COV-2
by: Elaine Haddock, et al.
Published: (2022-02-01)

Impairing RAGE signaling promotes survival and limits disease pathogenesis following SARS-CoV-2 infection in mice
by: Forrest Jessop, et al.
Published: (2022-01-01)

P54 ORAL ANTIVIRALS RITONAVIR-NIRMATRELVIR AND MOLNUPIRAVIR ARE HIGHLY EFFECTIVE IN PATIENTS WITH MULTIPLE MYELOMA AND COVID-19; A SINGLE-CENTER, PROSPECTIVE STUDY
by: V. Spiliopoulou, et al.
Published: (2023-05-01)

Combination regimen of nirmatrelvir/ritonavir and molnupiravir for the treatment of persistent SARS-CoV-2 infection: A case report and a scoping review of the literature
by: Davide Marangoni, et al.
Published: (2023-08-01)

Use of Oral Antivirals Ritonavir-Nirmatrelvir and Molnupiravir in Patients with Multiple Myeloma Is Associated with Low Rates of Severe COVID-19: A Single-Center, Prospective Study
by: Vassiliki Spiliopoulou, et al.
Published: (2023-03-01)

Antiviral efficacy of molnupiravir versus ritonavir-boosted nirmatrelvir in patients with early symptomatic COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial
by: Schilling, WHK, et al.
Published: (2023)

P1514: MOLNUPIRAVIR COMPARED TO NIRMATRELVIR/RITONAVIR FOR COVID-19 IN HIGH-RISK PATIENTS WITH HAEMATOLOGICAL MALIGNANCY IN EUROPE. A MATCHED-PAIRED ANALYSIS FROM THE EPICOVIDEHA REGISTRY
by: Jon Salmanton-García, et al.
Published: (2023-08-01)

Molnupiravir, Nirmatrelvir/Ritonavir, or Sotrovimab for High-Risk COVID-19 Patients Infected by the Omicron Variant: Hospitalization, Mortality, and Time until Negative Swab Test in Real Life
by: Luca Cegolon, et al.
Published: (2023-05-01)

Association of Molnupiravir and Nirmatrelvir-Ritonavir with preventable mortality, hospital admissions and related avoidable healthcare system cost among high-risk patients with mild to moderate COVID-19
by: Abraham Ka-Chung Wai, et al.
Published: (2023-01-01)

Computational Analysis of Molnupiravir
by: Artem V. Sharov, et al.
Published: (2022-01-01)

Real-World Study on Effectiveness of Molnupiravir and Nirmatrelvir–Ritonavir in Unvaccinated Patients with Chronic Respiratory Diseases with Confirmed SARS-CoV-2 Infection Managed in Out-Patient Setting
by: Wang Chun Kwok, et al.
Published: (2023-02-01)

Favipiravir (T-705) Protects IFNAR<sup>−/−</sup> Mice against Lethal Zika Virus Infection in a Sex-Dependent Manner
by: Keesha Matz, et al.
Published: (2021-05-01)

ChAdOx1 NiV vaccination protects against lethal Nipah Bangladesh virus infection in African green monkeys
by: Neeltje van Doremalen, et al.
Published: (2022-12-01)